Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 7 for:    N91115

MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects (SNO2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02013388
Recruitment Status : Completed
First Posted : December 17, 2013
Results First Posted : March 18, 2015
Last Update Posted : December 21, 2016
Sponsor:
Information provided by (Responsible Party):
Nivalis Therapeutics, Inc.

Brief Summary:
A study in healthy subjects to assess the safety, tolerability, and pharmacokinetics of N91115.

Condition or disease Intervention/treatment Phase
Healthy Drug: N91115 Drug: Placebo Drug: Placebo-Day 1 only Phase 1

Detailed Description:
This Phase 1 study in healthy subjects is being conducted to assess the safety, tolerability, and pharmacokinetics of N91115. Also, a comparison of the fasted versus fed with a high fat meal were compared for PK.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 49 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects
Study Start Date : February 2014
Actual Primary Completion Date : December 2014
Actual Study Completion Date : February 2015

Arm Intervention/treatment
Experimental: 10 mg
single oral daily dose of 10 mg N91115 for 14 days
Drug: N91115
Given PO daily for 14 days
Other Name: Cavosonstat

Placebo Comparator: Placebo
single oral daily dose of placebo for 14 days
Drug: Placebo
Given PO daily for 14 days

Experimental: 50 mg
single oral daily dose of 50 mg N91115 for 14 days
Drug: N91115
Given PO daily for 14 days
Other Name: Cavosonstat

Experimental: 50 mg (single dose)
single oral dose of 50 mg N91115
Drug: N91115
Given PO only on Day 1
Other Name: Cavosonstat

Experimental: 250 mg
single oral daily dose of 250 mg N91115 for 14 days (fasted)
Drug: N91115
Given PO daily for 14 days
Other Name: Cavosonstat

Experimental: 250 mg (Fed)
single oral daily dose of 250 mg N91115 for 1 day (fed fat meal)
Drug: N91115
Given PO only on Day 1
Other Name: Cavosonstat

Experimental: 500 mg
single oral daily dose of 500 mg N91115 for 14 days
Drug: N91115
Given PO daily for 14 days
Other Name: Cavosonstat

Placebo Comparator: Placebo-Day 1 only
Single oral dose of placebo (Day 1 only)
Drug: Placebo-Day 1 only
Given PO- only on Day 1 (single dosed to match single dose treatments)
Other Name: Placebo




Primary Outcome Measures :
  1. Safety and Tolerability of N91115 [ Time Frame: 21 Days ]
    Assessments are based on numbers of subjects with abnormal clinical evaluations, abnormal laboratory assessments, and adverse events.

  2. Pharmacokinetics: Day 1 AUClast [ Time Frame: Day 1 ]
    Day 1 AUClast plasma values from treatment groups completing 14 days of N91115 administration

  3. Pharmacokinetics: AUCtau Day 14 [ Time Frame: Day 14 ]
    Plasma analysis of AUCtau values from the end of the dosing period (Day 14) with N91115

  4. Pharmacokinetics: Day 1 Plasma Cmax Values [ Time Frame: Day 1 ]
    All subjects who completed sample collections for Day 1 plasma N91115

  5. Pharmacokinetics: Plasma Cmax Values on Day 14 [ Time Frame: Day 14 ]
    Plasma Cmax values from Day 14 subjects with repeat administration of N91115



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subject voluntarily agrees to participate in this study and signs an Institutional Review Board (IRB)-approved informed consent prior to performing any of the screening procedures and in the opinion of the PI complies with all the requirements of the study.
  • Subject is healthy, determined at the screening medical evaluation (including but not limited to medical history, physical examination and clinical laboratory evaluations).
  • Subject is Caucasian.
  • Female subject must be of non-childbearing potential (surgically sterile [hysterectomy or bilateral tubal ligation] or post-menopausal ≥ 1 year with follicle stimulating hormone [FSH] > 40 U/L). Women receiving hormone replacement therapy (HRT) are eligible to enroll.
  • Male subject must agree to use condoms and refrain from sperm donation from Day 1 until 30 days post last dose or have documentation of vasectomy.
  • Subject has a body weight > 50 kg and body mass index (BMI) between 19.5 and 32 kg/m2, inclusive, at screening.
  • Subject has no clinically significant abnormal findings related to their systolic or diastolic blood pressure (BP), per the investigator's judgment, at screening or Day 1.
  • Subject has no clinically significant abnormal findings in 12 lead ECG, per the investigator's judgment, at screening.

Exclusion Criteria:

  • Subject has clinically significant history or evidence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric disorder(s) as determined by the investigator or designee.
  • Subject has clinically significant abnormalities on a 12 lead ECG done at screening
  • Subject has clinically significant abnormalities on a 48-hour ambulatory ECG done at screening
  • Subject has any disorder that would interfere with the absorption, distribution, metabolism, or excretion of drugs.
  • Subject has any concurrent disease or condition that, in the opinion of the investigator, would make the subject unsuitable for participation in the clinical study.
  • Subject is unlikely to comply with the protocol requirements, instructions, and study related restrictions; e.g., uncooperative attitude, unavailable for follow-up call, and/or improbability of completing the clinical study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02013388


Locations
Layout table for location information
United States, Colorado
DaVita Clinical Research
Lakewood, Colorado, United States, 80228
Sponsors and Collaborators
Nivalis Therapeutics, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Christopher Galloway, MD Davita Clinical Research
Study Director: Steven A Shoemaker, MD Nivalis Therapeutics, Inc.

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Nivalis Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT02013388     History of Changes
Other Study ID Numbers: N91115-1H-01
First Posted: December 17, 2013    Key Record Dates
Results First Posted: March 18, 2015
Last Update Posted: December 21, 2016
Last Verified: November 2016

Keywords provided by Nivalis Therapeutics, Inc.:
N91115
GSNORi
SNO
Cavosonstat